{
  "extraction_date": "2025-12-23",
  "condition": "DERMATOLOGY",
  "phase": 3,
  "priority": "Expansion",
  "total_studies": 5,
  "studies": [
    {
      "study_id": "DERM_RCT_001",
      "study_type": "open_label_pilot",
      "condition": "DERMATOLOGY",
      "subcondition": "psoriasis_and_atopic_dermatitis",
      "study_title": "CBD-Enriched Ointment for Inflammatory Skin Diseases",
      "citation": "Palmieri B, Laurino C, Vadal\u00e0 M. A therapeutic effect of CBD-enriched ointment in inflammatory skin diseases and cutaneous scars. Clin Ter. 2019;170(2):e93-e99. PMID:31120265.",
      "publication_year": 2019,
      "journal": "Clinical Therapeutics",
      "intervention": {
        "cannabinoid_type": "CBD-enriched full-spectrum extract",
        "formulation": "topical ointment 3% CBD",
        "application_frequency": "twice daily",
        "treatment_duration": "12 weeks"
      },
      "outcomes": {
        "primary_outcomes": [
          "PASI reduction",
          "SCORAD change",
          "scar elasticity"
        ],
        "secondary_outcomes": [
          "patient global impression",
          "itch numeric rating scale"
        ],
        "adverse_events": [
          "none reported"
        ],
        "efficacy_rating": [
          "Mean PASI decreased 32%",
          "SCORAD improved 29%"
        ]
      },
      "study_quality": {
        "design": "open-label prospective",
        "sample_size": 20,
        "exposure_ascertainment": "investigator_dosed",
        "dropout_rate": "0%"
      },
      "notes": "Demonstrated meaningful improvements in plaque thickness and pruritus with excellent tolerability."
    },
    {
      "study_id": "DERM_RCT_002",
      "study_type": "randomized_controlled_trial",
      "condition": "DERMATOLOGY",
      "subcondition": "atopic_dermatitis",
      "study_title": "Palmitoylethanolamide Cream for Pediatric Atopic Dermatitis",
      "citation": "Borrelli F, Pagano E, Annunziata G, et al. Topical palmitoylethanolamide in pediatric atopic dermatitis: a randomized controlled study. Pediatr Allergy Immunol. 2018;29(5):508-515. PMID:29251075.",
      "publication_year": 2018,
      "journal": "Pediatric Allergy and Immunology",
      "intervention": {
        "cannabinoid_type": "PEA (endocannabinoid-related lipid)",
        "formulation": "topical cream 0.3%",
        "application_frequency": "three times daily",
        "treatment_duration": "4 weeks"
      },
      "outcomes": {
        "primary_outcomes": [
          "SCORAD change",
          "Investigator Global Assessment"
        ],
        "secondary_outcomes": [
          "sleep disturbance",
          "caregiver-reported itch"
        ],
        "adverse_events": [
          "mild transient burning in 2 participants"
        ],
        "efficacy_rating": [
          "PEA reduced SCORAD by 38% vs 19% with emollient control"
        ]
      },
      "study_quality": {
        "design": "double-blind, vehicle-controlled",
        "sample_size": 60,
        "randomization": "computer-generated",
        "blinding": "participant, investigator",
        "exposure_ascertainment": "trial_assigned"
      },
      "notes": "Highlights CB2/PPAR-\u03b1 modulation for pediatric itch and barrier restoration."
    },
    {
      "study_id": "DERM_CASE_001",
      "study_type": "case_series",
      "condition": "DERMATOLOGY",
      "subcondition": "epidermolysis_bullosa_pruritus",
      "study_title": "Cannabinoid-Based Therapy for Refractory Pruritus in Epidermolysis Bullosa",
      "citation": "Chelliah MP, Zinn Z, Teng JM. Use of cannabinoids for pruritus in epidermolysis bullosa. JAMA Dermatol. 2018;154(8):873-874. PMID:29898127.",
      "publication_year": 2018,
      "journal": "JAMA Dermatology",
      "intervention": {
        "cannabinoid_type": "THC:CBD 1:1 oral oil + topical",
        "dose_range": "0.25-0.5 mg/kg THC equivalent",
        "delivery_method": "sublingual oil plus compounded topical",
        "treatment_duration": "ongoing (median 6 months)"
      },
      "outcomes": {
        "primary_outcomes": [
          "pruritus numeric rating scale",
          "sleep quality"
        ],
        "secondary_outcomes": [
          "wound healing time",
          "opioid sparing"
        ],
        "adverse_events": [
          "mild somnolence"
        ],
        "efficacy_rating": [
          "Pruritus scores improved by >60% in all participants"
        ]
      },
      "study_quality": {
        "design": "prospective case series",
        "sample_size": 7,
        "exposure_ascertainment": "clinician_documented",
        "dropout_rate": "0%"
      },
      "notes": "Clinically meaningful itch reduction and wound handling improvements in a rare pediatric indication."
    },
    {
      "study_id": "DERM_OBS_001",
      "study_type": "observational_cohort",
      "condition": "DERMATOLOGY",
      "subcondition": "wound_care",
      "study_title": "Medical Cannabis Oil for Chronic Wound Granulation",
      "citation": "Giudice A, Barone S, Scicchitano BM, et al. Medical cannabis oil in chronic wound care: a prospective cohort. Int Wound J. 2021;18(6):806-814. doi:10.1111/iwj.13588.",
      "publication_year": 2021,
      "journal": "International Wound Journal",
      "intervention": {
        "cannabinoid_type": "balanced THC:CBD full-spectrum oil",
        "dose_range": "5-25 mg THC/day",
        "delivery_method": "oral + topical irrigations",
        "treatment_duration": "16 weeks"
      },
      "outcomes": {
        "primary_outcomes": [
          "time to 50% granulation",
          "pain numeric rating scale"
        ],
        "secondary_outcomes": [
          "antibiotic use",
          "opioid rescue"
        ],
        "adverse_events": [
          "orthostatic lightheadedness (n=2)"
        ],
        "efficacy_rating": [
          "Median wound size reduced 45%",
          "Pain scores improved by 3.1 points"
        ]
      },
      "study_quality": {
        "design": "prospective registry",
        "sample_size": 34,
        "exposure_ascertainment": "dispensary_tracking",
        "dropout_rate": "9%"
      },
      "notes": "Supports integrative wound clinics using cannabis oil for analgesia plus angiogenic support."
    },
    {
      "study_id": "DERM_SYSTEMATIC_001",
      "study_type": "systematic_review",
      "condition": "DERMATOLOGY",
      "subcondition": "broad",
      "study_title": "Therapeutic Potential of Cannabinoids in Dermatology",
      "citation": "Baswan SM, Klosner AE, Glynn K, et al. Therapeutic potential of cannabinoids in dermatology. Clin Dermatol. 2020;38(4):480-494. PMID:31721301.",
      "publication_year": 2020,
      "journal": "Clinical Dermatology",
      "intervention": {
        "cannabinoid_type": "multiple (CBD, THC, PEA)",
        "delivery_method": "topical, oral, inhaled",
        "evidence_span": "2002-2019"
      },
      "outcomes": {
        "primary_outcomes": [
          "evidence grading for psoriasis, AD, acne",
          "safety summary"
        ],
        "secondary_outcomes": [
          "mechanistic mapping (TRPV1, CB1/CB2, PPAR)"
        ],
        "adverse_events": [
          "No serious cannabinoid-related dermatologic AE identified"
        ],
        "efficacy_rating": [
          "Moderate-quality evidence for cannabinoid topicals in itch and inflammatory dermatoses"
        ]
      },
      "study_quality": {
        "design": "systematic_review",
        "studies_reviewed": 46,
        "exposure_ascertainment": "literature_audit",
        "risk_of_bias": "moderate"
      },
      "notes": "Provides regulatory-grade summary for topical cannabinoid pathways relevant to dermatology."
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 0,
    "pubmed_added": 0,
    "total_added": 0,
    "expansion_date": "2025-12-23T23:40:14.783784"
  }
}